ENDOSTATIN CONCENTRATION IN PLASMA OF HEALTHY HUMAN VOLUNTEERS
AbstractBackground: Angiogenesis is involved in many cardiovascular and cancerous diseases, including atherosclerosis and is controlled by a fine balance between angiogenic and angiostatic mediators. Endostatin is one of the main angiostatic mediators, and inhibits angiogenesis and prevents progression of atherosclerosis. The available literature shows a broad range of concentrations in relatively small samples of healthy controls and is calculated by using different techniques. This study was aimed to determine the basal endostatin concentration in plasma of healthy volunteers, to fully understand its physiological role. Methods: Fifty healthy adult volunteers were recruited to the study. Participants were advised not to participate in any physical activity on the day before the blood sampling. The volunteers’ physical activity, height, weight, heart rate and blood pressure were recorded. The samples were analysed for plasma endostatin concentration, using ELISA. The participants were divided by gender and ethnic groups to calculate any difference. Results: Endostatin and other variables were normally distributed. Most of the participants had a moderate level of physical activity with no gender related difference (p=0.370). The mean value for plasma endostatin in all samples was 105±12 ng/ml with range of 81–132 ng/ml. For males, it was 107±13 ng/ml, while for females; 102±12 ng/ml. There were no significant gender or ethnicity related differences in endostatin concentration. Moreover, endostatin was not significantly related with any anthropometric and physical variable. Conclusion: This study gives endostatin levels in normal healthy people and show no gender and ethnicity related differences in endostatin levels. Endostatin was not related with any anthropometric and physical variable.Keywords:Endostatin; Vascular endothelial growth factor; Angiogenesis; Atherosclerosis; Ethnic groups
O'Brien ER, Garvin MR, Dev R, Stewart DK, Hinohara T, Simpson JB, et al. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994;145(4):883–94.
Boehm T, Folkman J, Browder T, O'reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390(6658):404–7.
Eriksson K, Magnusson P, Dixelius J, Claesson-Welsh L, Cross MJ. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS lett 2003;536(1-3):19–24.
O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88(2):277–85.
Zeng X, Chen J, Miller YI, Javaherian K, Moulton KS. Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis. J Lipid Res 2005;46(9):1849–59.
Sasaki T, Hohenester E, Timpl R. Structure and Function of Collagen‐Derived Endostatin Inhibitors of Angiogenesis. IUBMB life 2002;53(2):77–84.
Deininger MH, Wybranietz WA, Graepler FT, Lauer UM, Meyermann R, Schluesener HJ. Endothelial endostatin release is induced by general cell stress and modulated by the nitric oxide/cGMP pathway. FASEB J 2003;17(10):1267–76.
Damico R, Kolb TM, Valera L, Wang L, Housten T, Tedford RJ, et al. Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;191(2):208–18.
Zorick TS, Mustacchi Z, Bando SY, Zatz M, Moreira-Filho CA, Olsen B, et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 2001;9(11):811–4.
Suhr F, Brixius K, de Marées M, Bölck B, Kleinöder H, Achtzehn S, et al. Effects of short-term vibration and hypoxia during high-intensity cycling exercise on circulating levels of angiogenic regulators in humans. J App Physiol (1985) 2007;103(2):474–83.
Craig CL, Marshall AL, Sjostrom M, Bauman A, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P: International Physical Activity Questionnaire: 12-country reliability and validity. Medicine and Science in Sports and Exercise. 2003, 35: 1381-1395.
Ständker L, Schrader M, Kanse SM, Jürgens M, Forssmann WG, Preissner KT. Isolation and characterization of the circulating form of human endostatin. FEBS lett 1997;420(2-3):129–33.
Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 2000;43(4):889.
Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 2000;6(12):4628–34.
Feldman AL, Alexander HR Jr, Bartlett DL, Kranda KC, Miller MS, Costouros NG, et al. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol 2001;8(9):741–5.
Feldman AL, Pak H, Yang JC, Alexander HR Jr, Libutti SK. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer 2001;91(8):1525–9.
Gu JW, Gadonski G, Wang J, Makey I, Adair TH. Exercise increases endostatin in circulation of healthy volunteers. BMC Physiol 2004;4(1):2.
Teh SH, Hill AD, Lee AW, Foley D, Kennedy S, Young L, et al. Raised plasma endostatin levels correlate inversely with breast cancer angiogenesis. J Surg Res 2004;116(1):165–71.
Sponder M, Dangl D, Stanek B, Kautzky-Willer A, Marculescu R, Sabri A, et al. Influence of age, smoking and T2 diabetes on exercise related antiangiogenic endostatin/collagen XVIII release in men. J Mens Health 2011;8(3):230–1.
Sponder M, Sepiol K, Lankisch S, Priglinger M, Kampf S, Litschauer B et al. Endostatin and physical exercise in young female and male athletes and controls. Int Sports Med 2014;35(13):1138–42.
Makey KL, Patterson SG, Robinson J, Loftin M, Waddell DE, Miele L, et al. Increased plasma levels of soluble vascular endothelial growth factor (VEGF) receptor 1 (sFlt-1) in women by moderate exercise and increased plasma levels of VEGF in overweight/obese women. Eur J Cancer Prev 2013;22(1):83–9.
Glenjen N, Mosevoll KA, Bruserud Ø. Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Int J Cancer 2002;101(1):86–94.
Bruserud Ø, Grovan F, Lindås R, Blymke Møinichen C, Østerhus KK. Serum levels of angioregulatory mediators in healthy individuals depend on age and physical activity: studies of angiogenin, basic fibroblast growth factor, leptin and endostatin. Scand J Clin Lab Invest 2005;65(6):505–12.
Brixius K, Schoenberger S, Ladage D, Knigge H, Falkowski G, Hellmich M, et al. Long-term endurance exercise decreases antiangiogenic endostatin signalling in overweight men aged 50–60 years. Br J Sports Med 2008;42(2):126–9.
Sponder M, Dangl D, Kampf S, Fritzer-Szekeres M, Strametz-Juranek J. Exercise increases serum endostatin levels in female and male patients with diabetes and controls. Cardiovasc Diabetol 2014;13(1):6.
Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol 1973;26(10):770–2.
Nocon M, Hiemann T, Müller-Riemenschneider F, Thalau F, Roll S, Willich SN. Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil 2008;15(3):239–46.